gp120/cd4

YYA-021 inhibits HIV entry, with high anti-HIV activity and low cytotoxicity.

Anti-Mouse CD4 Antibody (2G5.D) is an anti-mouse CD4 antibody widely used in research and experiments in the field of life sciences.

Ingenol mebutate (Ingenol 3-Angelate) is a potent activator of PKC subtypes including PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM. Ingenol mebutate exhibits antiinflammatory and antitumor activity.

(4S,5S)-(+)-Germacrone-4,5-epoxide inhibits certain subtypes of cytochrome P450 (CYP).

Moringin is an isothiocyanate obtained from myrosinase-mediated hydrolysis of the glucosinolate precursor glucoMoringin present in Moringa oleifera seeds. Moringin has anti-inflammatory and antioxidative properties.

Physalin H is an Hh signaling inhibitor blocks GLI1-DNA-complex formation, it also strong quinone reductase induction activity with IR (Induction ratio, QR induction activity) value of 3.74±0.02. Physalin H shows immunosuppressive effects on T cells both

Zanolimumab is a humanised monoclonal antibody targeting CD4, exhibiting cytotoxic and antiproliferative properties. By binding to the CD4 molecule and blocking T cell receptor (TCR) signalling, it is used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and T-cell lymphoma.

BMS-378806 (BMS-806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

3,5,6,7,8,3',4'-Heptemthoxyflavone exhibits neuroprotective, chemopreventive, anti-allergic, anti-inflammatory, immunomodulatory, anti-aging, and photoprotective effects; it inhibits collagenase activity, induces type I procollagen synthesis in HDFn cells, and combats nitric oxide (NO) carcinogenesis.

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

Fostemsavir Tris (BMS-663068 Tris) is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells.

NBD-556 is a small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

DS-003 is a small molecule Gp120 inhibitor. As an analog of BMS-378806, DS003 demonstrates enhanced inhibitory activity during prolonged exposure and when used in combination with fusion inhibitors. However, prior exposure to soluble CD4+ hinders DS003's binding to the viral envelope. Studies indicate that due to its targeting of the CD4+ binding site on Gp120, DS003 is a promising candidate for pre-exposure prophylactic therapy.

Fostemsavir (BMS-663068) is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

Temsavir (BMS626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.

Complestatin is a compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. It has a role as a metabolite, an antimicrobial agent and an anti-HIV-1 agent.

BMS-378806 is an orally bioavailable HIV-1 inhibitor that interferes with gp120-CD4 interaction.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl is an HIV-1 inhibitor that interacts with gp120, preventing its binding to CD4 and thereby maintaining CD4-dependent T cell function.

HIV Peptide T (Peptide T), this synthetic octapeptide is an antiviral drug in the treatment of HIV infection. It mainly competitively inhibits the interaction between gp120 (HIV surface protein) and the CD4 receptor, while also interacting with the vascular intestinal The peptide (vasointestinal peptide, VIP) receptor binds homologously and blocks the production and action of cytokines to exert its effect.

Retrocyclin-1, a Theta-defensin, selectively binds to carbohydrate-rich surface molecules such as fetuin, gp120 (K d =35.4 nM), CD4 (K d =31 nM), and galactosylceramide (K d =24.1 nM) [1], thereby shielding cells from HIV-1 infection.

VRC-01 is a human-derived IgG1 antibody that targets the envelope glycoprotein gp120 protein [gp120]. By partially mimicking the interaction between the CD4 receptor and the HIV-1 gp120 envelope glycoprotein, VRC-01 inhibits viral entry. For the isotype control of VRC-01, refer to HumanIgG1kappa, Isotype Control.